Invasive Mechanical Ventilation
Conditions
Interventions
Dexmedetomidine group:Drug: Dexmedetomidine
Ciprofol group:Drug: Ciprofol
Sponsors
The first people’s hospital of Changzhou
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Patients with an endotracheal intubation duration of =96 hours before enrollment 2.Patients with an anticipated mechanical ventilation duration of = 24 h 3.Patients with an anticipated sedation duration of = 24 h 4.Target RASS score -2 to +1 5.Age, =18 and <80 years, no gender limit, BMI =30 kg/m2
Exclusion criteria
Exclusion criteria: 1.Patients who are allergic to the study drugs, or patients with contraindications to the study drugs 2.Severe neurological disease or other medical conditions that makes it unable to give RASS score(Expected to require major surgery during ICU hospitalization) 3.Systolic blood pressure less than 90 mm Hg despite continuous infusions of 2 vasopressors before the start of study drug infusion. 4.Heart rate less than 50/min 5.second- or third- degree heart block (Patients with implanted pacemakers may not be excluded) 6.unstable angina pectoris or myocardial infarction 7.Patients with a moribund state and patients with an anticipated death in ICU 8.acute hepatitis or severe liver disease (Child-Pugh class C) 9.Patients who need neuromuscular blockers to promote mechanical ventilation 10.Patients who are unlikely to be taken off from mechanical ventilation 11.Patient is pregnant and/or lactating 12.Subject judged by the investigator to have any other factors unsuitable for participation in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the proportion of time in target sedation range (RASS score, -2 to +1);the propotion and the duration of bradycardia and hypotension; | — |
Secondary
| Measure | Time frame |
|---|---|
| Mean time within the target RASS range;Success rate of sedation;Recovery time;Median time of mechanical ventilation/Median time to extubation;28-day mechanical ventilation-free days;the total times of dose adjustments;Vital sign;Adverse events;ICU-LOS;28-day all-cause mortality; | — |
Countries
China
Contacts
Public ContactDaming Wang
The first people’s hospital of Changzhou
Outcome results
None listed